Zai Lab announces the inclusion of Augtyro for ROS1+ NSCLC and other updates in China’s National Reimbursement Drug List: Shanghai Saturday, November 30, 2024, 13:00 Hrs [IST] Z ...

Caption: Aubrey Kirschman is training for an Ironkids race to raise awareness and money for her dad's rare form of cancer. (Robert Kisrchman) The Kirschmans say they hope both Aubrey and their ...

When Aubrey Kirschman lines up at the starting line of the Ironkids race in Florida next month, she's going to be thinking ...

Zai Lab Limited (ZLAB) announced the inclusion of AUGTYRO (repotrectinib) in China's National Reimbursement Drug List for ROS1+ ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by ...

Shilpa Medicare’s joint venture Oncosol, with Shorla Oncology, has gained US FDA approval for IMKELDI, an imatinib oral ...

FDA has approved imatinib (IMKELDI), the first oral liquid tyrosine kinase inhibitor for treating leukemia and a range of cancers, including CML, GIST, and Ph+ ALL. Developed by Shorla Oncology ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

Kura Oncology Inc. (KURA) said that it has entered into a global strategic collaboration with Kyowa Kirin Co., Ltd. to develop and ...